Gracell Biotechnologies Inc GRCL Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$10.25 unchanged at close Nov 6
Last close · Previous close $10.25
- Market cap
- $693.92MAt the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$10.25unchangedPast month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$10.25Nov 5
- Volume0.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume0.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $10.25 to $10.25; now $10.25
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
GRCL beat the S&P 500 in 3 of 4 periods.
| Period | GRCL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GRCL: unchanged S&P 500: down 5.6% | GRCL beat the S&P 500 by 5.6 percentage points Beat |
| 3M | GRCL: unchanged S&P 500: down 4.1% | GRCL beat the S&P 500 by 4.1 percentage points Beat |
| Long term | ||
| 3Y | GRCL: up 139.5% S&P 500: up 75.0% +33.8% vs +20.5% a year | GRCL beat the S&P 500 by 64.5 percentage points Beat |
| 5Y | GRCL: down 11.9% S&P 500: up 67.8% −2.5% vs +10.9% a year | GRCL trailed the S&P 500 by 79.7 percentage points Trailed |
$10,000 invested in GRCL 5 years ago (Nov 5, 2021) would be worth about $8,813 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
GRCL beat the S&P 500 in 3 of 4 periods.
| Period | GRCL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GRCL: unchanged S&P 500: down 5.6% | GRCL beat the S&P 500 by 5.6 percentage points Beat |
| 3M | GRCL: unchanged S&P 500: down 4.3% | GRCL beat the S&P 500 by 4.3 percentage points Beat |
| Long term | ||
| 3Y | GRCL: up 139.5% S&P 500: up 68.8% +33.8% vs +19.1% a year | GRCL beat the S&P 500 by 70.7 percentage points Beat |
| 5Y | GRCL: down 11.9% S&P 500: up 56.9% −2.5% vs +9.4% a year | GRCL trailed the S&P 500 by 68.8 percentage points Trailed |
$10,000 invested in GRCL 5 years ago (Nov 5, 2021) would be worth about $8,813 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$30.57
Closing high on . Now 66.5% below that record.
Split-adjusted daily closes since Jan 8, 2021.
Stock splits
GRCL hasn’t split since its price history begins in 2021.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2023). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not reported
Other valuation measures
- 22.1×Book value as of Jun 30, 2023
Price relative to accounting equity (book value) per share on the Jun 30, 2023 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - $539.92MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2023 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own GRCL DCF in Excel. Value Gracell Biotechnologies with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY23, the quarter ended Jun 30, 2023. “Last 12 months” means the four quarters from Jul 1, 2022 to Jun 30, 2023, and balance-sheet figures are as of Jun 30, 2023.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- Not reported
- Net income
- Not reported
- Diluted EPS
- Not reported
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY21 (Sep 30, 2021) | $56.74K | −$20.04M | −$0.29 |
| Q4 FY21 (Dec 31, 2021) | $0.00 | −$20.09M | −$0.30 |
| Q1 FY22 (Mar 31, 2022) | $0.00 | −$24.78M | −$0.37 |
| Q2 FY22 (Jun 30, 2022) | $0.00 | −$21.84M | −$0.32 |
| Q3 FY22 (Sep 30, 2022) | $0.00 | −$23.88M | −$0.35 |
| Q4 FY22 (Dec 31, 2022) | $0.00 | −$18.75M | −$0.28 |
| Q1 FY23 (Mar 31, 2023) | Not reported | Not reported | Not reported |
| Q2 FY23 (Jun 30, 2023) | Not reported | Not reported | Not reported |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$32.40M | −$2.12 |
| FY21 (Dec 31, 2021) | $57.19K | −$70.59M | −$1.08 |
| FY22 (Dec 31, 2022) | $0.00 | −$87.16M | −$1.29 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- Not reportedLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flowNot reportedLast 12 months
- Capital spendingNot reportedLast 12 months
Shareholder returns
- Not reportedLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $164.09MAs of Jun 30, 2023
Cash plus short- and long-term marketable securities on the Jun 30, 2023 balance sheet.
- Total debt$21.82MAs of Jun 30, 2023
- Net cash$142.27MAs of Jun 30, 2023
- 6.44As of Jun 30, 2023
Current assets divided by current liabilities on the Jun 30, 2023 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.14As of Jun 30, 2023
Total debt divided by shareholders’ equity on the Jun 30, 2023 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
About Gracell Biotechnologies Inc
Gracell Biotechnologies Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- China
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
GRCL news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
GRCL stock FAQ
What is GRCL stock’s price today?
Gracell Biotechnologies (GRCL) traded at $10.25 at the close on , unchanged from the previous close of $10.25. Over the past 52 weeks it has traded between $10.25 and $10.25.
If you invested $1,000 in GRCL 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in GRCL on would be worth about $881 at the close on , a total return of −11.9%. Past performance doesn’t predict future returns.
What is Gracell Biotechnologies’s market cap?
Gracell Biotechnologies’s market capitalization is about $693.9 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $10.25 (how market cap works). Gracell Biotechnologies reported 338.50M shares outstanding at the end of its latest quarter ().
Does GRCL pay a dividend?
Gracell Biotechnologies hasn’t paid a dividend in the last twelve months.
What is GRCL’s 52-week high and low?
Over the past 52 weeks GRCL has traded as low as $10.25 and as high as $10.25. At $10.25 at the close on , it is 0.0% below that high and 0.0% above the low.
What is GRCL’s all-time high?
GRCL’s highest closing price was $30.57 on , adjusted for stock splits. At $10.25 at the close on , it is 66.5% below that record.
Has GRCL stock ever split?
No. GRCL hasn’t split since its price history begins in 2021.
What sector and industry is Gracell Biotechnologies in?
Gracell Biotechnologies is in the Healthcare sector and the Biotechnology industry, and is headquartered in China.
What exchange does GRCL trade on?
Gracell Biotechnologies trades on the Nasdaq under the ticker symbol GRCL. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.